ID | 1039 |
Name of the vaccine | Infanrix |
Microbe | Bacteria |
Disease name | Pertussis (Whooping Cough) |
Name of bacteria | Bordetella pertussis |
Type of vaccine | Inactivated |
Nucleic acid content | DNA |
Age | 6 weeks to 6 years |
Description of the vaccine | Diphtheria, tetanus toxoids, acellular pertussis vaccine adsorbed (DTaP vaccine). |
Name of the manufacturer | GlaxoSmithKline Biologicals and GSK Vaccines GmbH |
Name of the manufacturing country | Belgium and Germany |
Year of manufacture | 1997 |
Clinical Phase status | Approved |
Bacterial strain | Gram-negative coccobacillus. |
Efficacy | The efficacy against >=14 days of any cough or paroxysmal cough were 73% and 84%. |
Vaccine formulation | Suspension for injection |
Dosage | 0.5-mL injection given as a 5-dose series. One dose each at 2, 4, and 6 months. One booster dose at 15 to 20 months and another booster dose at 4 to 6 years. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | Prevents against diphtheria, tetanus and acellular pertussis. |
Export | Distributed by GlaxoSmithKline |
Approval | US FDA |
Adjuvant | Aluminium hydroxide |
Repurposing | Also for diphtheria and tetanus. |
Side effects of vaccine | Pain, redness, swelling, fever, drowsiness, irritability, loss of appetite. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.gov/media/75157/download |
Other name | NA |
Additional Links | NA
|